Annotation inferences using phylogenetic trees
Combined Automated Annotation using Multiple IEA Methods
Sulphatase activities are regulated by the interaction of sulphatase-modifying factor 1 with SUMF2.
-
The formylglycine (FGly) modification of an active-site cysteine, generated by SUMF1 within the ER, is required for the catalytic activity of the sulphatases (including GALNS); SUMF2 modulates SUMF1 activity.
Distinct effects of N-acetylgalactosamine-4-sulfatase and galactose-6-sulfatase expression on chondroitin sulfates.
The structure of human GALNS reveals the molecular basis for mucopolysaccharidosis IV A.
In-depth proteomic analyses of exosomes isolated from expressed prostatic secretions in urine.
Expression, activity and localization of lysosomal sulfatases in Chronic Obstructive Pulmonary Disease.
Mucopolysaccharidosis IV A: assignment of the human N-acetylgalactosamine-6-sulfate sulfatase (GALNS) gene to chromosome 16q24.
N-acetylgalactosamine-6-sulfate sulfatase in man. Absence of the enzyme in Morquio disease.
GALNS oligomer hydrolyses sulfate from Gal6S in keratan sulfate
Defective GALNS does not hydrolyse sulfate from Gal6S in keratan sulfate
Exocytosis of azurophil granule lumen proteins
UniProtKB P34059 (GALNS_HUMAN) curated record
-
FUNCTION: lysosomal enzyme that hydrolyzes sulfate groups from the glycosaminoglycans keratan sulfate and chondroitin-6-sulfate; SUBCELLULAR LOCATION lysosome; homodimer; formylglycine (3-oxoalanine) modification of Cys79 critical for activity; deficiency causes MPS4A (Morquio A).
"Lysosomal enzyme that hydrolyzes sulfate groups from
CC glycosaminoglycans (GAGs), keratan sulfate (KS) and chondroitin-6-
CC sulfate (C6S)."
Keratan sulfate degradation
MPS IV - Morquio syndrome A
Mucopolysaccharidosis type IVA. N-acetylgalactosamine-6-sulfate sulfatase exonic point mutations in classical Morquio and mild cases.
Molecular testing of 163 patients with Morquio A (Mucopolysaccharidosis IVA) identifies 39 novel GALNS mutations.